Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 16,500 | |||
5 mg | 在庫あり | ¥ 35,500 | |||
10 mg | 在庫あり | ¥ 55,000 | |||
25 mg | 在庫あり | ¥ 112,000 | |||
50 mg | 在庫あり | ¥ 160,000 | |||
100 mg | 在庫あり | ¥ 226,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 45,500 |
ターゲット&IC50 | EGFR:34 nM, ErbB2:33 nM |
分子量 | 574.05 |
分子式 | C31H29ClFN5O3 |
CAS No. | 848133-17-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (19.16 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HKI-357 848133-17-5 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HKI357 Inhibitor HKI 357 ErbB-1 HER1 inhibit NSCLCs Epidermal growth factor receptor ERBB2 inhibitor